Participants with known congestive heart failure (CHF); if known, patients with left ventricular ejection fraction (LVEF) =< 40% are excluded
History of myocardial infarction =< 6 months, current symptomatic CHF or left ventricular ejection fraction (LVEF) < 40% or > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
Left ventricular ejection fraction (LVEF) ?50%. A lower LVEF (?40%) is permissible if a formal cardiologic evaluation reveals no evidence for clinically significant functional impairment, otherwise the subject may not enter the study.
Left ventricular ejection fraction (LVEF) < 45%
Participants must have a left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 45%
Participants must have a left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) < 50%, regardless of whether there are symptoms of heart failure
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
Systolic cardiac function will be assessed at screening if clinically indicated by history and physical; only patients with left ventricular ejection fraction (LVEF) >= 50% will be eligible for enrollment
Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%
Left ventricular ejection fraction (LVEF) within normal institutional limits
Left ventricular ejection fraction (LVEF) > 45%
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
Cardiac: Asymptomatic or if symptomatic, then left ventricular ejection fraction (LVEF) at rest must be >= 40% and must improve with exercise.
Known left ventricular ejection fraction (LVEF) < 40%. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF 40%?50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
Patients who have a left ventricular ejection fraction (LVEF) < 45% at screening.
Left Ventricular Ejection Fraction (LVEF) >/=50% HER2-Expressing Breast Cancer-Specific Inclusion Criteria
Left ventricular ejection fraction (LVEF) >= 50%;
Any patient known to have an left ventricular ejection fraction (LVEF) =< 45 percent (%)
Has a left ventricular ejection fraction (LVEF) ?50% by either an ECHO or MUGA within 28 days before registration
Uncontrolled cardiac disease, or myocardial infarction within the last 12 months, or left ventricular ejection fraction (LVEF) < 50%, or QTcF interval > 470 msec
Left ventricular ejection fraction (LVEF) >= 55%
Left ventricular ejection fraction (LVEF) >= ULN (institutional limit)
Left ventricular ejection fraction (LVEF) of >= 40%
Left ventricular ejection fraction (LVEF) >= 45%
Have left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to enrollment.
Left ventricular ejection fraction (LVEF) >= 50%
History of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < 40%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) of >= 50%
Left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 40 percent (%)
Left ventricular ejection fraction (LVEF) <50% at screening.
Patients with left ventricular ejection fraction (LVEF) < 40%
Left ventricular ejection fraction (LVEF) > 40%
Left ventricular ejection fraction (LVEF) ? 50%
Left ventricular ejection fraction (LVEF) >= 45%
Adequate cardiac function with left ventricular ejection fraction (LVEF) ? 55% at baseline.
Left ventricular ejection fraction (LVEF) below 45% or lifetime exposure to anthracyclines over 350mg/m2 of daunorubicin equivalent
Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] greater than or equal to 50%)
Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] >/= 45%)
Left ventricular ejection fraction (LVEF) ? 50%
Subjects must have a left ventricular ejection fraction (LVEF) of >= 45%
LVEF (left ventricular end diastolic function) of >= 45%; LVEF between 45% and 54% must have negative stress test with increase in ejection fraction (EF) of 3-5 points with stress
Left ventricular ejection fraction (LVEF) >= 45%; LVEF assessment must have been performed within 8 weeks of enrollment
Left ventricular ejection fraction (LVEF) >= 40% on ECHO or MUGA
Left ventricular ejection fraction (LVEF) > 40%
Left ventricular ejection fraction (LVEF) >= 40%
Left Ventricular Ejection Fraction (LVEF) ? 50%.
Baseline left ventricular ejection fraction (LVEF) >= 40%
Cardiac left ventricular ejection fraction (LVEF) > 45%
Left ventricular end diastolic function (LVEF) of >= 50%
Asymptomatic or if symptomatic then left ventricular ejection function (LVEF) at rest must be >= 50% and must improve with exercise
Any patient known to have left ventricular ejection fraction (LVEF) =< 45%
Left ventricular end diastolic function (LVEF) of >= 50%
Left ventricular ejection fraction (LVEF) of >= 45%
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exercise
LVEF (left ventricular ejection fraction) >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricle ejection fraction (LVEF) >= 30%
Left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction (LVEF) <40%
Adequate cardiac function defined by a left ventricular ejection fraction (LVEF) ?40%, QTc <450 msec, and no evidence of clinically significant dysrhythmias on ECG
Left ventricular ejection fraction (LVEF) > 45%
Cardiac left ventricular ejection fraction (LVEF) > 45%
Patients must have a left ventricular ejection (LVEF) >= 50% within 56 days of enrollment
Left ventricular ejection fraction (LVEF) >= 40%, no uncontrolled arrhythmias or symptomatic cardiac disease.
Measurement of left ventricular ejection fraction (LVEF) should be performed in patients with prior anthracycline exposure or known history of arrhythmia or structural heart disease; in these cases, LVEF must be >= 40%
Left ventricular ejection fraction (LVEF) > 50%
Left ventricular ejection fraction (LVEF) </= 40 percent (%) at screening
Left ventricular ejection fraction (LVEF) >= 50%
Cardiac insufficiency: left ventricular ejection fraction (LVEF) < 50% or coronary artery disease requiring treatment
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50%
Left ventricle ejection fraction (LVEF) >= 55%, specimens must be collected within 10 days prior to the start of study treatment
Left ventricular ejection fraction (LVEF) >= institutional normal
Baseline left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) =< 50%
Left ventricular ejection fraction (LVEF) >= 45% corrected
Contraindication to any drug in the chemotherapy regimen, and specifically: LVEF (Left Ventricular Ejection Fraction) < 45% or peripheral neuropathy grade 2
Left ventricular ejection fraction (LVEF) < 50%;
Subject has a resting left ventricular ejection fraction (LVEF) of ? 40% obtained by echocardiography.
left ventricular ejection fraction (LVEF) of 50% or higher at baseline
LVEF at least 50%
Left ventricular ejection fraction (LVEF) >= 55%
Left ventricular ejection fraction (LVEF) > 50%
LVEF < 50%
Left ventricular ejection fraction (LVEF) < 40%
Have LVEF (left ventricular ejection fraction) <50% at screening
Left ventricular ejection fraction (LVEF) >= 50% (measured within 28 days of study entry)
Left ventricular ejection fraction (LVEF) ? 40%
Baseline left ventricular ejection fraction (LVEF) 50%.
Left ventricular ejection fraction (LVEF) >= 40%
A left ventricular ejection fraction (LVEF) must be > 50
Cardiac: left ventricular ejection fraction (LVEF) at rest ? 35% (RIC cohort) or LVEF at rest ? 40% (FIC cohort), or left ventricular shortening fraction (LVFS) ? 25%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50% for patients enrolling in the HER2 directed therapy arm
Left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to randomization.
Left ventricular ejection fraction (LVEF) ? 40% within the 21 days prior to randomization
Left ventricular ejection fraction (LVEF) >= 50% performed no more than 4 weeks prior to enrollment
If the left ventricular ejection fraction (LVEF) < 40, patients will be excluded
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) of >= 50%
Left ventricular ejection fraction (LVEF) >= 45% if patient has known cardiac dysfunction history
Left ventricular ejection fraction (LVEF) >= 50%
Subjects must have a left ventricular ejection fraction (LVEF) of >= 45%
Normal left ventricular ejection fraction (LVEF)
REGISTRATION INCLUSION CRITERIA: Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of > 55% performed no more than 4 weeks prior to randomization
Baseline left ventricular ejection fraction (LVEF) value less than (<) 55 percent (%)
Asymptomatic cardiac function or if symptomatic then left ventricular ejection fraction (LVEF) >= 50% and must improve with exercise
Uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction (LVEF) < 45%
Resting left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50%
Patients must have a left ventricular ejection fraction (LVEF) of >= 60% AND/OR
Left ventricular ejection fraction (LVEF) >/= 50% within 28 days prior to first dose of study drug administration
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 40%
The patient has an absence of coexisting medical problems that would significantly increase the risk of the chemotherapy procedure (e.g. poor left ventricular ejection fraction [LVEF<40%])
Left ventricular ejection fraction (LVEF) >= 50%
History of documented congestive heart failure (CHF) or systolic dysfunction (left ventricular ejection fraction [LVEF] < 50%)
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exercise
Left ventricular ejection fraction (LVEF) of > 50% by Doppler ultrasound assessment
Patient must have a normal left ventricular ejection fraction (LVEF) (>= 53%); if a patient has a borderline LVEF (40-52%) they may be considered after consultation with cardiology and study principal investigator (PI) and treated per the guidelines
Left ventricular ejection fraction (LVEF) >= 45%
Subjects > age 60 or with clinical signs of heart disease must have ejection fraction >= 45% left ventricular ejection fraction (LVEF) pre-transplant
Left ventricular ejection fraction (LVEF) >= 40%, however, subjects with a LVEF in the range of 40-49% should have cardiology clearance prior to intervention
Participants with a history of chronic heart failure must have cardiac ECHO indicating left ventricular ejection fraction (LVEF) ? 45% within 21 days prior to first dose of study drug
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise
Left ventricular ejection fraction (LVEF) of >= 50%
Subjects who have a history of, or current evidence of uncontrolled cardiovascular disease or a left ventricular ejection fraction (LVEF) <50%
Adequate left ventricular ejection fraction (LVEF) ? 50%
Left ventricular ejection fraction (LVEF) less than 45%
Cardiac left ventricular ejection fraction (LVEF) >= 35%
Known left ventricular ejection fraction (LVEF) < 50%
Left Ventricular Ejection Fraction (LVEF) ? 50% Part 1:
Left ventricular ejection fraction (LVEF) < 50%
Left ventricular ejection fraction (LVEF) >= 50 %
LVEF
If the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limits
LVEF (left ventricular ejection fraction) >= 50%
Patients with left ventricular ejection fraction (LVEF) < 45% will not be eligible
Left ventricular ejection fraction (LVEF) < 40%
Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
Left ventricular ejection fraction (LVEF) ? 40%.
Left ventricular ejection fraction (LVEF) of at least 55%
Left ventricular ejection fraction (LVEF) >= 40%
Left ventricular ejection fraction (LVEF) >= 40%
Left ventricular ejection fraction (LVEF) >= 50%
LVEF of at least 50%
Left ventricular ejection fraction (LVEF) >= 50 %
Left ventricular ejection fraction (LVEF) >= 35% (within 42 days)
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise
Left ventricular ejection fraction (LVEF) >= 50%
If previously measured, left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction (LVEF) >= 40%
Left ventricular ejection fraction (LVEF) < 50%
Patients must have left ventricular ejection fraction (LVEF) > 45% or within institutional normal limits
Patients with a history of left ventricular (LV) dysfunction will be still candidates for enrollment in the study if they have documented left ventricular ejection fraction (LVEF) recovery (most recent documented LVEF of 50% or higher) for at least 6 months prior to SPECT regardless of current cardiac medication regimen
Left ventricular ejection fraction (LVEF) ? 40%
Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%
